Avenell A., Broom J., Brown T. J., Poobalan A., Aucott L., Steran S. C., Smith W. C., Jung R. T., Campbell M. K.Grant A. M. (2004), ‘Systematic review of the long-term effects and economic consequences of treatments of obesity and implications for health improvement’, Health Technology Assessment, 8(iii–iv): 1–182.
Bobinac A., van Exel N. J. A., Rutten F. F. H.Brouwer W. B. F. (2010), ‘Willingness to pay for a QALY: the individual approach’, Value in Health, 13(8): 1046–1055.
Bobinac A., van Exel N. J. A., Rutten F. F. H.Brouwer W. B. F. (2011a), ‘Get more, pay more? An elaborate test of the validity of willingness to pay per QALY estimates’, Journal of Health Economics, doi:10.1016/j.jhealeco.2011.09.004.
Bobinac A., Brouwer W. B. F.van Exel N. J. A. (2011b), ‘Societal discounting and growing healthy life expectancy – an empirical investigation’, Health Economics, 20(1): 111–119.
Brouwer W. B. F. (2009), ‘The Basis of the Package’. Inaugural lecture, Erasmus University Rotterdam.
Brouwer W. B. F., Rutten F. F. H.Koopmanschap M. A. (2001), ‘Costing in Economic Evaluations’, in M. F. Drummond and A. McGuire (eds), Economic Evaluation in Health Care: Merging Theory with Practice, New York: Oxford University Press.
Brouwer W. B. F., Niessen L. W., Postma M. J.Rutten F. F. H. (2005), ‘Need for differential discounting of costs and health effects in cost effectiveness analyses’, British Medical Journal, 331: 446–448.
Brouwer W. B. F., van Exel N. J. A., van Baal P. H. M.Polder J. J. (2007), ‘Economics and public health: engaged to be happily married!’, European Journal of Public Health, 17: 122–123.
Brouwer W. B. F., van Exel N. J. A., Baker R.Donaldson C. (2008), ‘The new myth: the social value of a QALY’, PharmacoEconomics, 26: 1–4.
Claxton K., Paulden M., Gravelle H., Brouwer W. B. F.Culyer A. J. (2011), ‘Discounting and decision making in the economic evaluation of health-care technologies’, Health Economics 20: 2–15.
Claxton K., Sculpher M.Drummond M. (2002), ‘A rational framework for decision making by the National Institute for Clinical Excellence (NICE)’, Lancet, 360: 711–715.
Committee on Choices in Health Care (Dunning Committee) (1992), Choices in Health Care, Rijswijk, the Netherlands: Ministry of Welfare Health and Cultural Affairs.
CVZ (Health Care Insurance Board) (2006), Package Management in Practice, Diemen: CVZ, [in Dutch].
CVZ (Health Care Insurance Board) (2009a), Package Management in Practice 2, Diemen: CVZ, [in Dutch].
CVZ (Health Care Insurance Board) (2009b), Smoking Cessation Program: Care to be Insured, Diemen: CVZ, [in Dutch].
de Bekker-Grob E. W., Polder J. J., Mackbach J. P.Meerding W. J. (2007), ‘Towards a comprehensive estimate of national spending on prevention’, BMC Public Health, 7: 252.
de Wit A.Brouwer W. B. F. (2004), ‘Economische evaluaties van GVO programma's: Belangrijk, lastig, en te weinig gedaan’, Tijdschrift voor Gezondheidswetenschappen, 82: 129–132 [in Dutch].
Dirkmaat T., van Genugten M. L. L.de Wit G. A. (2003), Cost Effectiveness of Prevention – an Exploratory Study, Bilthoven, the Netherlands: National Institute for Public Health and the Environment (RIVM), [in Dutch, English abstract].
Dranove D. (2003), What's Your Life Worth?, New Jersey: FT/Prentice-Hall.
Drummond M. F., Sculpher M. J., Torrance G. W., O'Brian B. J.Stoddart G. L. (2005), Methods for the Economic Evaluation of Health Care Programmes, 3rd edition, New York: Oxford University Press Inc.
Eichler H.-G., Kong S. X., Gerth W. C., Mavros P.Jönsson B. (2004), ‘Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness tresholds expected to emerge?’, Value in Health, 7: 518–528.
Elley R., Kerse N., Arroll B., Swinburn B., Ashton T.Robinson E. (2004), ‘Cost-effectiveness of physical activity counseling in general practice’, New Zealand Medical Journal, 117(1207): U1216.
Feenstra T. L., Hamberg-van Reenen H. H., Hoogenveen R. T.Rutten-van Molken M. P. (2005), ‘Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modelling study’, Value in Health, 8: 178–190.
Feenstra T. L., van Baal P. H. M., Gandjour A.Brouwer W. B. F. (2008), ‘Future costs in economic evaluation: a comment on Lee’, Journal of Health Economics, 27: 1645–1649.
Garber A. M.Phelps C. E. (1997), ‘Economic foundations of cost-effectiveness analysis’, Journal of Health Economics, 16: 1–31.
Gravelle H.Smith D. (2001), ‘Discounting for health effects in cost-benefit and cost-effectiveness analysis’, Health Economics, 10: 587–599.
Gravelle H., Brouwer W. B. F., Niessen L. W., Postma M. J.Rutten F. F. H. (2007), ‘Discounting in economic evaluations: stepping forward towards optimal decision rules’, Health Economics, 16: 307–317.
Haslam D. W.James W. P. T. (2005), ‘Obesity’, Lancet, 366: 1197–1209.
Herman W. H., Hoerger T. J., Brandle M., Hicks M., Sorensen S., Zhang P., Hamman R. F., Ackermann R. T., Engelgau M. M.Ratner R. E., Diabetes Prevention Program Research Group (2005), ‘The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance’, Annals of Internal Medicine, 142: 323–332.
Hirth R. A., Chernew M. E., Miller E., Fendrick A. M.Weissert W. G. (2000), ‘Willingness to pay for a quality-adjusted life year: in search of a standard’, Medical Decision Making, 20: 332–342.
Hollander A. E. M., de Hoeymans N., Melse J. M., van Oers J. A. M.Polder J. J. (2006), Public Health Forecast 2006, Houten, the Netherlands: Bohn Stafleu Van Loghum, [in Dutch, English abstract].
Johannesson M. (2001), ‘Should we aggregate relative or absolute changes in QALYs?’, Health Economics, 10: 573–577.
Johansson S. E.Sundquist J. (1999), ‘Change in lifestyle factors and their influence on health status and all-cause mortality’, International Journal of Epidemiology, 28: 1073–1080.
Jonson A. R. (1986), ‘Bentham in a box: technology assessment and health care allocation’, Law, Medicine & Health Care, 14: 172–174.
Keeler E. B.Cretin S. (1983), ‘Discounting of life-saving and other non-monetary effects’, Manage Science, 29: 300–306.
Koopmanschap M. A., Rutten F. F. H., van Ineveld B. M.van Roijen L. (1995), ‘The friction cost method for measuring indirect costs of disease’, Journal of Health Economics, 14: 171–189.
Mackenbach J. M. (2010), Disease in the Netherlands. Health Between Politics and Biology, Amsterdam: Elsevier Gezondheidszorg, [in Dutch].
McCabe C., Claxton K.Culyer A. J. (2008), ‘The NICE cost-effectiveness threshold: what it is and what that means’, PharmacoEconomics, 26: 733–744.
Meltzer D. (1997), ‘Accounting for future costs in medical cost-effectiveness analysis’, Journal of Health Economics, 16: 33–64.
Meltzer D.Johannesson M. (1999), ‘Inconsistencies in the “societal perspective” on costs of the panel on cost-effectiveness in health and medicine’, Medical Decision Making, 19: 371–377.
Nord E. (2005), ‘Concerns for the worse off: fair innings versus severity’, Social Science & Medicine, 60: 257–263.
Nyman J. A. (2004), ‘Should the consumption of survivors be included as a cost in cost-utility analysis?’, Health Economics, 13: 417–427.
Lee R. H. (2008), ‘Future costs in cost effectiveness analysis’, Journal of Health Economics, 27: 809–818.
Organisation for Economic Co-operation and Development (OECD) (2005), Health at a Glance: OECD Indicators 2005, Paris: OECD Publishing.
Rappange D. R., Brouwer W. B. F., Rutten F. F. H.van Baal P. H. M. (2010), ‘Lifestyle intervention: from cost savings to value for money’, Journal of Public Health, 32: 440–447.
Rappange D. R., van Baal P. H. M., van Exel N. J. A., Feenstra T. L., Rutten F. F. H.Brouwer W. B. F. (2008), ‘Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?’, PharmacoEconomics, 26: 815–830.
Rawlins M. D.Culyer A. J. (2004), ‘National institute for clinical excellence and its value jugdements’, British Medical Journal, 329: 224–227.
Ronckers E. T., Groot W.Ament A. J. H. A. (2005), ‘Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness’, Medical Decision Making, 25: 437–448.
RVZ (Council for Public Health and Care) (2006), Sensible and Sustainable Care, The Hague: RVZ, [in Dutch].
RVZ (Council for Public Health and Care) (2007), Fair and Sustainable Care, The Hague: RVZ, [in Dutch].
Saha S., Gerdtham U.-G.Johansson P. (2010), ‘Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases’, International Journal of Environmental Research and Public Health, 7: 3150–3195.
Schreyögg J., Stargardt T., Velasco-Garrido M.Busse R. (2005), ‘Defining the “health benefit basket” in nine european countries: evidence from the European Union Health BASKET project’, European Journal of Health Economics, 6, (Supplement 1): 2–10.
Statistics Netherlands (CBS) (2004), Health Accounts 2003, Voorburg, the Netherlands: Statistic Netherlands, [in Dutch].
Stolk E. A., Brouwer W. B. F.van Busschbach J. J. V. (2002), ‘Rationalising rationing: economic and other considerations in the debate about funding of Viagra’, Health Policy, 59: 53–63.
Stolk E. A., van Donselaar G., Brouwer W. B. F.van Busschbach J. J. V. (2004), ‘Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall’, PharmacoEconomics, 22: 1097–1107.
Stolk E. A., Pickee S. J., Ament A. H. J. A.Busschbach J. J. V. (2005), ‘Equity in health care prioritisation: an empirical inquiry into social value’, Health Policy, 74: 343–355.
Stolk E. A., de Bont A., van Halteren A. R., Bijlmer R. J.Poley M. J. (2009), ‘Role of health technology assessment in shaping the benefits package in the Netherlands’, Expert Reviews of Pharmacoeconomics & Outcomes Research, 9: 85–94.
van Baal P. H. M., Feenstra T. L., Hoogenveen R. T., de Wit G. A.Brouwer W. B. F. (2007), ‘Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a “perfect” cost-utility ratio’, Health Economics, 16: 421–433.
van Baal P. H. M., Polder J. J., Hoogenveen R. T., Engelfriet P. M., Boshuizen H. C., Feenstra T. L., de Wit G. A.Brouwer W. B. F. (2008), ‘Prevention no cure for rising expenditures: lifetime medical costs of obesity’, PLoS Medicine, 5(2): e29 (0242–0249).
Vijgen S. M. C., Busch M. C. M., de Wit G. A., van Zoest F.Schuit A. J. (2005), Economic Evaluation of Prevention – Opportunities for Dutch Public Health Policy, Bilthoven, the Netherlands: National Institute for Public Health and the Environment (RIVM), [in Dutch, English abstract].
Weinstein M. C.Stason W. B. (1977), ‘Foundations of cost-effectiveness analysis for health and medical practices’, New England Journal of Medicine, 296: 716–721.
Williams A. (1997), ‘Intergenerational equity: an exploration of the fair innings argument’, Health Economics, 6: 117–132.